We believe in challenging conventional methods to bring the benefits of nature to everyone. Your customers and your industry demand the safest ingredients available. Few can deliver. We can. Our leading biotechnology platform allows us to deliver consistent, economical, sustainable ingredients at a global scale.
Using the instructions contained in the genes of plants, we can produce the same compounds at higher purity, speed, consistency, and cost-effectiveness, but smaller environmental impact than traditional agriculture practices.
Our innovative research platform reinvents the production of molecules for global pharmaceutical, health and wellness, and consumer packaged goods industries.
We are building to meet big needs – and small too. From kilos to metric tons, our platform provides the ability to scale production to meet the needs of our clients.
The supply chain for our platform technology is far simpler than plant-based production. Manufacturing infrastructure is already in place to meet the demand of clients across the globe.
With extensive experience in industrial biotechnology and an impressive background in launching successful businesses, our team possesses all the tools needed for success.
More than half of our experienced science and technical team have PhDs and our business team is responsible for cofounding five companies in senior executive roles, which in total sold for over $4 billion.
About Us
Not everyone can do what we do. We are an elite team of scientists and business leaders pioneering how synthetic biology can bring the best of nature’s ingredients to market.
Management Team
Dr. Seufer-Wasserthal has more than 25 years’ experience in the biotechnology industry. He was previously Chief Commercial Officer at Sestina Bio, LLC and Chief Business Officer of Origenis GmbH and served in various business development roles at Intrexon, Codexis and Evotec. Dr. Seufer Wasserthal received his PhD from the Technical University of Graz in Austria and published widely in the then starting field of synthetic biology.
Mr. Doupe has over 18 years’ experience in financial leadership roles, principally in the international oil and gas industry, during which time he provided corporate strategic direction while overseeing all aspects of financial operations, including budgeting and planning, treasury, accounting, tax, reporting and investor relation functions. Over half of Mr. Doupe’s 18 years of financial experience has been in various Chief Financial Officer roles, principally in publicly listed companies. Mr. Doupe has been active with various industry and non-profit groups throughout his career, most recently as the Treasurer and Board Member of the Canada Council for the Americas – Alberta and he holds a CPA,CA designation and a Bachelor of Management degree from the University of Calgary.
Dr. Savile has 17 years’ experience in science, commercial, and operations roles in biotech. He is a highly experienced scientist and operations expert focused on the scale up and commercialization of biobased processes for pharma, food & beverage, and energy. Dr. Savile has acted as technical leader and commercial program manager on several large R&D programs that led to commercial processes (see, for example: Science 2010, 329, 305-309, U.S. Patent 8,293,507, PNAS 2014, 111, 16436-16441, U.S. Patent 8,288,141). In addition, Dr. Savile has published more than 25 articles, book chapters, and patents related to development of biobased process with a focus on transformative chemistries and difficult- to-synthesize products. Prior to Willow, Dr. Savile worked at Codexis, Zymergen, and Intrexon. He received his PhD in Organic Chemistry from McGill University in 2005.
Dr. Choudhary has over 15 years’ experience in R&D and technical operations driving rapid optimization of biological systems for industrial biotech and food applications. She is highly experienced in developing high throughput strain engineering platforms to enable scale up and production of commercially relevant compounds. She has a proven track record of enabling innovative technologies from initial concept through development by building and leading high performing, multidisciplinary teams. She received her PhD from Macquarie University, NSW, Australia in 2008 and holds 6 granted patents (additional 7 patents pending).
Dr. Seufer-Wasserthal has more than 25 years’ experience in the biotechnology industry. He was previously Chief Commercial Officer at Sestina Bio, LLC and Chief Business Officer of Origenis GmbH and served in various business development roles at Intrexon, Codexis and Evotec. Dr. Seufer Wasserthal received his PhD from the Technical University of Graz in Austria and published widely in the then starting field of synthetic biology.
More than 25 years of experience as a lawyer and executive in diverse industries. Current Chair of the Board of Crescent Point Energy Corp. Has served as an executive in several customer-centric and diverse industries, as EVP, Corporate Services and General Counsel for WestJet Airlines Ltd., the Assistant General Counsel, Upstream at Imperial Oil Ltd., and the Senior Vice President, Legal/IP & General Counsel, Corporate Secretary for SMART Technologies Inc. A member of the Institute of Corporate Directors and has extensive corporate governance experience. Holds a Bachelor of Commerce, Finance degree and a Bachelor of Laws degree, both from the University of Calgary. Admitted to the Law Society of Alberta in 1991 and holds the ICD.D designation.
Mr. Foreman has over 20 years of professional experience in private equity, corporate finance, and financial technology. Mr. Foreman is currently a Partner and the Chief Investment Officer of Tuatara Capital, L.P. Prior to co-founding Tuatara Al was a Managing Director at Highbridge Principal Strategies, and earlier was a Managing Director at J.P. Morgan in the Financial Sponsors Group and Private Equity Fund Services business. Previously, Al held executive roles at Vitech Systems Group and Virtual Growth, and he began his career at Citigroup. Mr. Foreman earned a B.S. in Finance from the University of Connecticut and a dual J.D./MBA from Arizona State University.
Mr. Lalani has been Chief Financial Officer of Kelt Exploration Ltd. since October 2012 and Vice President since October 2017. Before that, Mr. Lalani was Chief Financial Officer & Vice President, Finance of Celtic Exploration Ltd. from October 2002 to February 2013. He has over 25 years’ experience in leadership positions. Mr. Lalani holds a Bachelor of Commerce degree from the University of Calgary.
Mr. Archibald is an independent businessman and the Executive Chairman of Cequence Energy Ltd. and a director of Spartan Delta Corp. Mr. Archibald was a former director and audit committee member of numerous public issuers, including Spartan Energy Corp. from December 2013 to May 2018 when it was acquired for approximately $1.4 billion by Vermilion Energy Inc. and Spartan Oil Corp. from June 2011 to January 2013 when it completed a business combination with Bonterra Energy Corp. for a total transaction value of approximately $480 million. Mr. Archibald has held senior executive positions with a number of public and private issuers, including roles as President of Cypress Energy Corp., Chairman and Chief Executive Officer of Cyries Energy Inc. and President and Chief Executive Officer of Cequel Energy Inc. He holds a Bachelor of Commerce Degree and a Masters of Business Administration.
Dr. Kalantzis has been co-founder of several public companies in his 25 years’ experience and is currently the President and CEO of Spartan Delta Corp. Dr. Kalantzis has been instrumental in a number of significant transactions including in his capacity as a senior officer with Spartan Energy Corp. from December 2013 to May 2018, Spartan Oil Corp. from June 2011 to January 2013, Spartan Exploration Ltd. (public) from September 2010 to June 2011 and Spartan Exploration Ltd. (private) from January 2008 to September 2010. Dr. Kalantzis holds an MSc from the University of Saskatchewan and a PhD from the University of Alberta and has published and presented many papers in international journals and conferences.
Mr. Peters is an experienced executive having co-founded four start-up companies in the past 15 years. Mr. Peters has raised over $1.0 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4.0 billion on sale. Mr. Peters previously was Chief Financial Officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.
Our research lab employs over thirty science and technical staff in close proximity to allied university research and biotechnology hubs.
Please direct inquiries to our head office in Calgary, AB
Phone: +1 403-910-5140
Email: info@willowbio.com
Willow Biosciences Inc.
Suite 202 – 1201 5th Street SW Calgary, AB Canada T2R 0Y6
Sound like you?
Investors
News
Phone: +1 403 910 5140
Email: info@willowbio.com
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.